Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT trial)
Jump to navigation
Jump to search
Introduction
400 patients with diabetes, hypertension & osteoarthritis
standard doses of celecoxib, rofecoxib or naproxen
Results:
- after 12 weeks, rofecoxib group showed higher mean 24 hour systolic blood pressure (134 vs 130 mm Hg)
References
- ↑ Journal Watch 25(6):45-46, 2005
Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, Kivitz A, van Ingen H, Brabant T, Fort JG; Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med. 2005 Jan 24;165(2):161-8. Erratum in: Arch Intern Med. 2005 Mar 14;165(5):551. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15668361